Philippe P. Pagni
Novo Nordisk
Risk analysis (engineering)Internal medicineEndocrinologyAntigenPsychologyCD8ReceptorMHC class IChemistryImmunologyBeta cellCombination therapyCognateImmunotherapyNOD miceAnimal modelRobustness (economics)Cell and molecular biologyCytokineMHC class IIAutoimmune diseasePeptideInsulinQuality (business)InsulitisImmunosuppressionGlycemicType 1 diabetesTLR2LiraglutideHuman physiologyDrug targetCD40Process (engineering)BiochemistryDiabetes mellitusNodReplication (computing)MedicineInterleukinImmune system
Publications 6
#1Philippe P. Pagni (Novo Nordisk)H-Index: 4
#2Chaplin Jay (Novo Nordisk)
Last. Shangjin Li (Novo Nordisk)
view all 16 authors...
Type 1 diabetes is an autoimmune disease in which insulin-secreting β-cells are destroyed, leading to a life-long dependency on exogenous insulin. There are no approved disease-modifying therapies available, and future immunotherapies would need to avoid generalized immune suppression. We developed a novel plasmid expressing preproinsulin2 and a combination of immune-modulatory cytokines (transforming growth factor-beta-1, interleukin [IL] 10 and IL-2) capable of near-complete prevention of auto...
#1Philippe P. Pagni (Novo Nordisk)H-Index: 4
#2Anitra C. Wolf (Novo Nordisk)H-Index: 1
Last. Ken Coppieters (Novo Nordisk)H-Index: 17
view all 8 authors...
#1Matthias von Herrath (Novo Nordisk)H-Index: 70
#2Philippe P. Pagni (Novo Nordisk)H-Index: 4
Last. Jacob Sten Petersen (Novo Nordisk)H-Index: 5
view all 7 authors...
Recent articles have highlighted the lack of reproducibility of data from scientific publications. Here we would argue that a better way to describe and also tackle this matter is to use the term " ...
#2Nikole Perdue (Novo Nordisk)H-Index: 3
#3Philippe P. Pagni (Novo Nordisk)H-Index: 4
Last. Tamar E. Boursalian (Novo Nordisk)H-Index: 2
view all 11 authors...
Abstract Immunotherapy for type 1 diabetes (T1D) has previously focused on suppressing the autoimmune response against pancreatic beta cells to preserve endogenous insulin production and regulate glucose levels. With increased attention toward combination therapy strategies, studies indicate the multifunctional cytokine interleukin-21 (IL-21) may be a suitable target as an immuno-modulatory arm, while glucagon-like peptide-1 receptor (GLP-1R) agonists may be appropriate as a beta cell protective...
#1Juha Grönholm (NIH: National Institutes of Health)H-Index: 8
#2Philippe P. Pagni (Novo Nordisk)H-Index: 4
Last. Michael J. Lenardo (NIH: National Institutes of Health)H-Index: 110
view all 8 authors...
Aims/hypothesis Insulin is widely considered to be a driver antigen in type 1 diabetes in humans and in mouse models of the disease. Therefore, insulin or insulin analogues are candidates for tolerogenic drugs to prevent disease onset in individuals with risk of diabetes. Previous experiments have shown that autoimmune diabetes can be prevented in NOD mice by repeated doses of insulin administered via an oral, nasal or parenteral route, but clinical trials in humans have not succeeded. The hypog...
#1Ghanashyam Sarikonda (La Jolla Institute for Allergy and Immunology)H-Index: 9
#2Sowbarnika Sachithanantham (La Jolla Institute for Allergy and Immunology)H-Index: 7
Last. Matthias von Herrath (Novo Nordisk)H-Index: 70
view all 6 authors...
Abstract Type 1 diabetes (T1D) is characterized by the immune-mediated destruction of pancreatic beta cells leading to inadequate glycemic control. Trials with immunomodulatory monotherapies have shown that the disease course can in principle be altered. The observed preservation of endogenous insulin secretion however is typically transient and chronic treatment is often associated with significant side effects. Here we combined anti-CD3 with the Hsp60 peptide p277, two drugs that have been eva...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.